Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "GST"

281 News Found

JBCPL to acquire brands from Sanzyme for Rs 628 cr
News | January 26, 2022

JBCPL to acquire brands from Sanzyme for Rs 628 cr

Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021


Lupin to acquire supplements portfolio of Anglo-French Drugs & Industries for Rs 325 crore
News | January 18, 2022

Lupin to acquire supplements portfolio of Anglo-French Drugs & Industries for Rs 325 crore

The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category


Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’
Sustainability | January 13, 2022

Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’

The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People


Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Barentz appoints Daniel Hitz as CEO, APAC
People | January 07, 2022

Barentz appoints Daniel Hitz as CEO, APAC

Hitz shall assume new role from January 17th, 2022


NATHEALTH Home Care Forum launches white paper on healthcare delivery
Healthcare | January 06, 2022

NATHEALTH Home Care Forum launches white paper on healthcare delivery

10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies


Expectations and predictions for 2022
Opinion | December 28, 2021

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc